NRx Subsidiary GeNeuro Wins European Patent for ALS Drug Candidate GNK-301
NRXP has more than doubled off its 52-week low of $1.62 on light trading volume (0.4× avg).
Summary
GeNeuro, an NRx subsidiary, secured a European patent (EP 3 570 878 B1) covering GNK-301, a monoclonal antibody targeting HERV-K envelope protein implicated in ALS. The patent adds to two existing US patents and strengthens IP protection for a program that has shown neurotoxicity-blocking effects in preclinical models. GNK-301 is now in cGMP manufacturing with Phase 1 trials planned for H2 2027. This follows GeNeuro's August 2026 selection in the CDMRP ALS grant competition, signaling continued momentum in the ALS pipeline. For a company with a $147M market cap and a going concern warning, a new patent and advancing clinical program provide a meaningful, if early-stage, positive development.
At the time of this announcement, NRXP was trading at $3.40 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $147.2M. The 52-week trading range was $1.62 to $5.06. This news item was assessed with positive market sentiment and an importance score of 7 out of 10. Source: GlobeNewswire.